Ligand binding by estrogen receptor beta attached to nanospheres measured by flourescence correlation spectroscopy

Cytometry Part A

Volumn 69, Issue 6, 2006, Pages 524-532

  Allen, Noah W ^a   Thompson, Nancy L ^b  

^a UNIVERSITY OF NORTH CAROLINA AT ASHEVILLE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Estradiol; FCS; Kinetics; Nuclear receptor; SERM; Steroid receptor coactivator

Indexed keywords

AVIDIN; BIOTIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR BETA; FLUORESCENT DYE; LIGAND; NEUTRAVIDIN; PEPTIDE; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; UNCLASSIFIED DRUG; NANOTUBE;

ANALYTIC METHOD; ARTICLE; AUTOCORRELATION; BIOTINYLATION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN; LIGAND BINDING; MATERIAL COATING; MEASUREMENT; METHODOLOGY; NANOPARTICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RELIABILITY; REPRODUCIBILITY; SAMPLE SIZE; SIGNAL DETECTION; KINETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; SPECTROFLUOROMETRY;

AVIDIN; BIOTIN; ESTROGEN RECEPTOR BETA; HUMANS; KINETICS; LIGANDS; NANOTUBES; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE; TAMOXIFEN;

EID: 33746581094     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20279     Document Type: Article

References (27)

1. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur J Cancer 1999;35: 1974-1985.
2. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL. Effects of tamoxifen on cardiovascular risk-factors in postmenopausal women. Ann Int Med 1991;115:860-864.
3. Schwabe JWR, Chapman L, Finch JT, Rhodes D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell 1993;75: 567-578.
4. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-937.
5. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
6. Mosselman W, Polman J, Dijkema R. ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392: 49-53.
7. Pike ACW, Brzozowski AM, Hubbard RE, Bonn T, Thorsell A-G, Engstrom O, Ljunggren J, Gustafsson J-A, Carlquist M. Structure of the ligand-binding domain of oestregen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-4618.
8. McDonnell DP The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999;10:301-311.
9. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J-A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863-870.
10. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
11. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-551.
12. Chen CL, Weiss N, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741.
13. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger K. Serum estradiol levels and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-220.
14. Lee JE, Chung KE, Han W. Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells. Anticancer Res 2004;24: 3961-3964.
15. Iannone MA, Consler TG, Pearce KH, Stimmel JB, Parks DJ, Gray JG. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 2001;44:326-337.
16. Tinoco I, Sauer K, Wang JC. Physical Chemistry: Principles and Applications in Biological Sciences, 3rd ed. Englewood Cliffs, NJ: Prentice Hall; 1995.
17. Thompson NL. Fluorescence correlation spectroscopy. In Lakowicz JR, editor. Topics in Fluorescence Spectroscopy. New York: Plenum Press; 1991. P 337.
18. Krichevsky O, Bonnet G. Fluorescence correlation spectroscopy: The technique and its applications. Rep Prog Phys 2002;65:251-297.
19. Margeat E, Poujol N, Boulahtouf A, Chen Y, Muller JD, Gratton E, Cavailles V, Royer CA. The human estrogen receptor α dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. J Mol Biol 2001;306:433-442.
20. Christoph S, Meyer-Almes F-J. Novel fluorescence based receptor binding assay method for receptors lacking ligand conjugates with preserved affinity: Study on estrogen receptor a. Biopolymers 2003; 72:250-263.
21. Thenot S, Bonnet S, Boulahtouf A, Margeat E, Royer CA, Borgna J-L, Cavailles V. Effect of ligand and DNA binding on the interaction between human transcription intermediary factor 1a and estrogen receptors. Mol Endocrinol 1999;13:2137-2150.
22. Zhou GC, Cummings R, Li Y, Mitra S, Wilkinson HA, Elbrecht A, Hermes JD, Schaeffer JM, Smith RG, Moller DE. Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer. Mol Endocrinol 1998;12:1594-1604.
23. Gee AC, Carlson KE, Martini PGV, Katzenellenbogen BS, Katzenellenbogen JA. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor Mol Endocrinol 1999;13:1912-1923.
24. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA. Estrogen receptor dimerization. Ligand binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol 2002;16:2706-2719.
25. Tamrazi A, Carlson KE, Katzenellenbogen JA. Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 2003;17:2593-2602.
26. Suen C-S, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998;273:27645-27653.
27. Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG. Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci USA 2002;99:8562-8567.